Avricore Health Inc. Files August 2024 6-K Report
Ticker: AVCRF · Form: 6-K · Filed: Sep 6, 2024 · CIK: 1355736
| Field | Detail |
|---|---|
| Company | Avricore Health INC. (AVCRF) |
| Form Type | 6-K |
| Filed Date | Sep 6, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: reporting, foreign-private-issuer, company-update
TL;DR
AVRICORE HEALTH INC. (AVRX) FILED ITS AUGUST 6-K REPORT. NOTHING MAJOR, JUST STANDARD FOREIGN PRIVATE ISSUER FILING.
AI Summary
Avricore Health Inc. filed a Form 6-K on September 6, 2024, for the reporting period ending August 31, 2024. The company, formerly known as Vanc Pharmaceuticals Inc., NUVA Pharmaceuticals Inc., and ALDA Pharmaceuticals Corp., is headquartered at 1120-789 West Pender St, Vancouver, BC, V6C 1H2. This filing is a report of a foreign private issuer.
Why It Matters
This filing provides routine updates for Avricore Health Inc. as a foreign private issuer, which is important for investors tracking the company's compliance and reporting status.
Risk Assessment
Risk Level: low — This filing is a routine report for a foreign private issuer and does not appear to contain significant new financial or operational information that would immediately impact risk.
Key Players & Entities
- Avricore Health Inc. (company) — Registrant
- Vanc Pharmaceuticals Inc. (company) — Former Company Name
- NUVA Pharmaceuticals Inc. (company) — Former Company Name
- ALDA Pharmaceuticals Corp. (company) — Former Company Name
- September 6, 2024 (date) — Filing Date
- August 31, 2024 (date) — Reporting Period End Date
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers required to be filed with the SEC to provide information that the issuer has made or is required to make public pursuant to the laws of its home country or that it has filed or is required to file with a stock exchange on which its securities are traded.
What is Avricore Health Inc.'s primary business classification?
Avricore Health Inc. is classified under Pharmaceutical Preparations (SIC code 2834).
When was Avricore Health Inc. last known to change its name?
The company was formerly known as Vanc Pharmaceuticals Inc. and its name was changed on September 11, 2014.
What is the fiscal year end for Avricore Health Inc.?
Avricore Health Inc.'s fiscal year ends on December 31.
Does Avricore Health Inc. file annual reports under Form 20-F or 40-F?
Avricore Health Inc. indicates that it files annual reports under Form 20-F.
Filing Stats: 379 words · 2 min read · ~1 pages · Grade level 17.7 · Accepted 2024-09-06 16:07:30
Filing Documents
- form6-k.htm (6-K) — 20KB
- ex1.htm (EX-1) — 59KB
- ex2.htm (EX-2) — 263KB
- ex3.htm (EX-3) — 211KB
- ex4.htm (EX-4) — 14KB
- ex5.htm (EX-5) — 14KB
- ex1_001.jpg (GRAPHIC) — 10KB
- ex2_001.jpg (GRAPHIC) — 28KB
- ex3_001.jpg (GRAPHIC) — 21KB
- 0001493152-24-035302.txt ( ) — 665KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. AVRICORE HEALTH INC. Date: September 6, 2024 By “Kiki Smith” Kiki Smith Chief Financial Officer